Supply of medicines in clinical trials: impact on safety, traceability and cold chain

O clinical trial drug supply takes on a strategic role. More than an operational step, it directly influences the safety of participants, the reliability of data and the success of clinical trials.

Clinical research has advanced consistently in recent years. Especially in areas such as oncology, rare diseases and advanced therapies, new drugs depend on rigorous studies before reaching the patient.

In addition, investigational drugs have specific characteristics. That's why they require a structured, validated and fully regulatory-compliant logistics chain.

Supply of medicines in highly complex clinical studies

In clinical trials, the supply of medicines goes far beyond delivery to the research center. It involves planning, control and coordination between different agents in the chain.

In addition, many of these drugs have limited stability, small volumes and require a cold chain. As a result, any failure can jeopardize not only the product, but the entire clinical study.

According to international World Health Organization (WHO), The integrity of the supply chain is essential to guarantee safety, quality and scientific reliability.

Among the main challenges in the supply of drugs in clinical research are:

• Demand planning according to study protocol
• Distribution to multiple centers and countries
• Strict control of temperature and environmental conditions
• Compliance with Good Clinical Practice (GCP)
• Continuity of supply throughout the study

Thus, supply becomes a critical factor for the viability of the research.

Traceability for clinical research

Another key point in the supply of medicines is traceability. Each batch needs to be identified, monitored and documented at every stage.

In addition, regulatory bodies such as FDA and EMA reinforce the need for auditable records and transparent processes. This guarantees rapid responses in the event of deviations, protocol adjustments or regulatory requirements.

Traceability is therefore not just a regulatory requirement. It also protects the scientific integrity of the study and the safety of the patients involved.

Cold chain as a pillar

Most of the medicines used in clinical research, especially biologicals and advanced therapies, depend on strict thermal control. For this reason, the cold chain has become indispensable in the supply of medicines.

According to IQVIA Institute, Temperature control failures are among the main causes of loss of high-value drugs in clinical trials.

Therefore, the supply needs to take into account:

• Continuous temperature monitoring
• Validated and qualified processes
• Contingency plans for thermal deviations
• Complete technical documentation and reports

In this way, the stability of the medicine is preserved from start to finish.

The supply of medicines and the advance of advanced therapies

As cell, gene and personalized therapies gain ground, the supply of medicines becomes even more complex. Unlike traditional models, these therapies are often produced on demand.

What's more, lead times are shorter and volumes are smaller. Logistics therefore need to be highly coordinated and specialized.

In this scenario, the supply of medicines is no longer just operational support. It now plays a direct role in the success of health innovation.

Supply of medicines in clinical research

O clinical trial drug supply is one of the pillars of modern clinical research and advanced therapies. When structured with traceability, a cold chain and regulatory compliance, it contributes directly to patient safety and the scientific quality of studies.

Therefore, as medicine evolves, so does the need for logistics chains prepared to deal with sensitive products, strict protocols and global operations. The supply of medicines is thus becoming a strategic element in health innovation.